Passage Bio Inc expected to post a loss of 80 cents a share - Earnings Preview

Passage Bio

31/10/2022 15:16

* Passage Bio Inc  PASG.OQ   PASG.O  is expected to show no
change
in quarterly revenue when it reports  results on November 2
(estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Passage Bio Inc is
for a
loss of 80 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Passage Bio
Inc
is $10​, above​ its last closing price of $1.28. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2022  -0.79       -0.83      -0.73     Beat    11.7
 Mar. 31 2022  -0.91       -0.89      -0.79     Beat    11
 Dec. 31 2021  -0.90       -0.89      -0.95     Missed  -7.2​
 Sep. 30 2021  -0.89       -0.86      -0.87     Missed  -1
 ​​Jun.        -0.76       -0.76      -0.90     Missed  -18.9
 30 2021                                                
 Mar. 31 2021  -0.75       -0.74      -0.76     Missed  -2.2​
 Dec. 31 2020  -0.69       -0.70      -0.85     Missed  -21
 Sep. 30 2020  -0.78       -0.76      -0.63     Beat    17.1
 This summary was machine generated October 31 at 15:16 GMT.  All
figures in US dollars  unless otherwise stated